Navelbine(vinorelbine) is an active drug for breast cancer and it can be used as single agent, or in combinations. Vinorelbine, a novel vinca alkaloid derivative developed in France, has been widely used for the treatment of breast cancer and non-small cell lung cancer since the 1990s and there are many reports of phase II studies in the 1990s. In Japan alone, there were six trials during this time period. Response rates are around 20%. NCCN lists vinorelbine on p.46 of its Breast cancer Guideline as a single agent.
Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 19:2722-2730, 2001.
Toi M, Saeki T, Aogi K, Sano M, Hatake K, Asaga T, Tokuda Y, Mitsuyama S, Kimura M, Kobayashi T, Tamura M, Tabei T, Shin E, Nishimura R, Ohno S, Takashima S.
Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes.Jpn J Clin Oncol. 2005 Jun;35(6):310-5.